Unternehmen wird geladen
Protagonist Therapeutics, Inc.
PTGX · Nasdaq · ·
130,83 $-2,6 %Schluss 13. Nov.
Zahlen bis 30. September 2026, aus dem 10-Q vom 6. November 2026
Wertentwicklung in der Vergangenheit
- 1W
- -0,9 %
- 1M
- -4,2 %
PTGX · Nasdaq · ·
130,83 $-2,6 %Schluss 13. Nov.
Zahlen bis 30. September 2026, aus dem 10-Q vom 6. November 2026
Just reported
From Protagonist Therapeutics's results release of 5. November 2026; its quarterly report has since been filed.
Actual
274,4M $
+29 % q/q
Guided
—
No guide given
Actual
3,07 $
+34 % q/q
Guided
—
No guide given
Actual
218,3M $
+38 % q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Protagonist Therapeutics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,6B $A+
EXELExelixis, Inc.16,8B $A+
JAZZJazz Pharmaceuticals plc15,5B $A
TECHBIO-Techne Corp11,4B $A+
HALOHalozyme Therapeutics, Inc.11,4B $A+Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21. Okt. 2026CBGraded C, now B
MCKMckesson Corporation4. Nov. 2026BAGraded B, now A
CVSCVS Health Corp4. Nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4. Nov. 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28. Okt. 2026CAGraded C, now AIcotyde (icotrokinra)
An oral peptide medicine that blocks the interleukin-23 receptor, a part of the immune system involved in plaque psoriasis. It is approved in the United States for plaque psoriasis and is licensed to Janssen.
Rusfertide
An injected medicine that imitates hepcidin, a natural hormone that regulates iron. It is being reviewed by U.S. regulators as a treatment for polycythemia vera, a rare disease in which the body makes too many red blood cells.
PN-881
An oral peptide medicine that blocks interleukin-17, an immune-system signal involved in inflammatory skin diseases. It is being studied as a possible treatment for psoriasis and related conditions.
PN-477
A peptide designed to activate the glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon receptors. It is being developed for obesity in oral and injectable forms.
PN-458
A peptide designed to activate the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors. It is being developed for obesity in oral and injectable forms.
PN-8047
An oral small-molecule medicine designed to imitate hepcidin and regulate iron. It is being developed as a possible treatment for polycythemia vera.
Protagonist discovers and develops medicines, including peptide drugs made from short chains of amino acids. It licenses Icotyde to Janssen, part of Johnson & Johnson, which is responsible for its development and commercialization; Protagonist can receive milestone payments and royalties on sales. Takeda has the worldwide rights to develop and commercialize rusfertide, while Protagonist also advances medicines of its own for immune diseases, blood disorders and obesity.
Gebaut aus den eigenen Einreichungen von Protagonist Therapeutics, Inc. bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.
Protagonist licenses medicines for psoriasis and a rare blood disorder to drug companies, which pay milestone fees and royalties, while developing treatments for obesity.
Grade A+
Das Band unter dem Kurs zeigt die Note an jedem Tag – gebildet nur aus den Unterlagen, die bis dahin veröffentlicht waren.
Zeigt 2 von 27 Quartalen der Notenhistorie von Protagonist Therapeutics, Inc.. Die übrigen 25 reichen zurück bis März 2019.